Pulse.

a daily field guide to health research that matters

◆ Console

‹ Sun · 1 Nov 2026
Standard addition

The impact of PROgnostic SIgnatures in stage II colon cancer patients enrolled in the phase III clinical trial TOSCA: the PROSIT study.

Researchers identified an immune signature in stage II colon cancer that predicts worse outcomes, offering a path to identify patients who might benefit from intensified treatment.

This prospective clinical-trial correlative transcriptomic study examined The impact of PROgnostic SIgnatures in stage II colon cancer patients enrolled in the phase III clinical trial TOSCA: the PROSIT study. In this study, whole-transcriptome profiling of high-risk stage II CRC from the prospective TOSCA trial identified an Immune Exclusion (IE) signature associated with significantly shorter disease-free survival, which remained associated with DFS after adjustment for MSI status and tumor sidedness.

What the study was

Study design
Prospective clinical-trial correlative transcriptomic study
Category
Genomics/Precision Medicine
Maturity
Validated
Journal
Translational oncology

Why it surfaced

Abstract-backed prospective clinical-trial correlative transcriptomic study relevant to Precision oncology and genomic medicine; scored conservatively because full text was not assessed.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.